Literature DB >> 29340995

Is bacteremia the decisive factor for the duration of antimicrobial therapy in bacteremic urinary tract infections?

Stamatis Karakonstantis1, Dafni Korela2, Dimitra Kalemaki3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29340995     DOI： 10.1007/s15010-018-1114-8

Source DB:  PubMed          Journal:  Infection        ISSN： 0300-8126            Impact factor:   3.553


× No keyword cloud information.
  5 in total

Review 1.  International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases.

Authors:  Kalpana Gupta; Thomas M Hooton; Kurt G Naber; Björn Wullt; Richard Colgan; Loren G Miller; Gregory J Moran; Lindsay E Nicolle; Raul Raz; Anthony J Schaeffer; David E Soper
Journal:  Clin Infect Dis       Date:  2011-03-01       Impact factor: 9.079

2.  A Seven-Day Course of TMP-SMX May Be as Effective as a Seven-Day Course of Ciprofloxacin for the Treatment of Pyelonephritis.

Authors:  Miriam T Fox; Michael T Melia; Rebecca G Same; Anna T Conley; Pranita D Tamma
Journal:  Am J Med       Date:  2017-02-16       Impact factor: 4.965

3.  Optimal duration of antimicrobial therapy for uncomplicated Gram-negative bloodstream infections.

Authors:  Avery N Nelson; Julie Ann Justo; P Brandon Bookstaver; Joseph Kohn; Helmut Albrecht; Majdi N Al-Hasan
Journal:  Infection       Date:  2017-05-06       Impact factor: 3.553

Review 4.  Duration of antibiotic treatment for acute pyelonephritis and septic urinary tract infection-- 7 days or less versus longer treatment: systematic review and meta-analysis of randomized controlled trials.

Authors:  Noa Eliakim-Raz; Dafna Yahav; Mical Paul; Leonard Leibovici
Journal:  J Antimicrob Chemother       Date:  2013-05-21       Impact factor: 5.790

5.  Treatment duration of febrile urinary tract infection: a pragmatic randomized, double-blind, placebo-controlled non-inferiority trial in men and women.

Authors:  Cees van Nieuwkoop; Willize E van der Starre; Janneke E Stalenhoef; Anna M van Aartrijk; Tanny J K van der Reijden; Albert M Vollaard; Nathalie M Delfos; Jan W van 't Wout; Jeanet W Blom; Ida C Spelt; Eliane M S Leyten; Ted Koster; Hans C Ablij; Martha T van der Beek; Mirjam J Knol; Jaap T van Dissel
Journal:  BMC Med       Date:  2017-04-03       Impact factor: 8.775
  5 in total
  1 in total

1.  Reply to comments: duration of antimicrobial therapy for Gram-negative bacteremia secondary to urinary source of infection.

Authors:  Majdi N Al-Hasan; Avery N Nelson; Julie Ann Justo; Helmut Albrecht; Joseph Kohn; P Brandon Bookstaver
Journal:  Infection       Date:  2018-02-07       Impact factor: 3.553
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.